Table 3.
Baseline characteristics according to miR-22 expression status.
| Low miR-22 Expression (n = 26) | High miR-22 Expression (n = 15) | p-Value | |
|---|---|---|---|
| Median age | 63 (42–86) | 60 (23–79) | 0.422 |
| Sex (M/F) | 16/10 | 10/5 | 0.743 |
| Disease subtypes | 0.061 | ||
| MDS-SLD | 1 (3.8) | 1 (6.7) | |
| MDS-MLD | 4 (15.4) | 6 (40.0) | |
| MDS-EB1 | 5 (19.2) | 6 (40.0) | |
| MDS-EB2 | 9 (34.6) | 2 (13.3) | |
| MDS-U | 1 (3.8) | 0 (0.0) | |
| CMML | 5 (19.2) | 0 (0.0) | |
| 5q-syndrome | 1 (3.8) | 0 (0.0) | |
| IPSS risk categories Low Intermediate-1 Intermediate-2 High Lower-risk disease * Higher-risk disease * |
2 (7.7) 10 (38.5) 10 (38.5) 4 (15.4) 12 (46.2) 14 (53.8) |
0 (0.0) 11 (73.3) 4 (26.7) 0 (0.0) 11 (73.3) 4 (26.7) |
0.149 0.091 |
| IPSS-R risk categories | 0.429 | ||
| Very low | 1 (3.8) | 0 (0.0) | |
| Low | 3 (11.5) | 4 (26.7) | |
| Intermediate | 6 (23.1) | 5 (33.3) | |
| High | 9 (34.6) | 2 (13.3) | |
| Very high | 7 (26.9) | 4 (26.7) | 0.183 |
| Lower-risk disease * | 10 (38.5) | 9 (60.0) | |
| Higher-risk disease * | 16 (61.5) | 6 (40.0) | |
| Cytogenetic abnormality | 9 (34.6) | 6 (40.0) | 0.730 |
| Cytogenetic risk categories | |||
| Very good | 1 (3.8) | 1 (6.7) | 0.757 |
| Good | 20 (76.9) | 10 (66.7) | |
| Intermediate | 1 (3.8) | 1 (6.7) | |
| Poor | 1 (3.8) | 1 (6.7) | |
| Very poor | 3 (11.5) | 2 (13.3) | |
| Lower-risk karyotype ◊ | 21 (80.8) | 11 (73.3) | 0.701 |
| Higher-risk karyotype ◊ | 5 (19.2) | 4 (26.7) | |
| Poor-risk gene mutation | 11 (42.3) | 6 (40.0) | 0.885 |
| Transfusion requirement | 23 (88.5) | 11 (73.3) | 0.390 |
Abbreviations: CMML, chronic myelomonocytic leukemia; IPSS, International Prognostic Scoring System; IPSS-R, Revised International Prognostic Scoring System; MDS-SLD, MDS-single lineage dysplasia; MDS-MLD, MDS-multilineage dysplasia; MDS-EB1, MDS-excess blasts-1; MDS-EB2, MDS-excess blasts-2; MDS-U, MDS-unclassified. * Based on IPSS and IPSS-R, patients are divided into lower-risk disease (IPSS low, intermediate-1; IPSS-R very low, low, intermediate) and higher-risk disease (IPSS Intermediate-2, high; IPSS-R high, very high) groups. ◊ Based on the IPSS-R, cytogenetic risk categories are divided into lower-risk karyotype (IPSS-R very good, good) and higher-risk karyotype (IPSS-R intermediate, poor, very poor).